Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23391717 | 0.91 | HDAC3 (0.33) | DDB1CRBNCYP4F2CYP4A11 | |
| SCHEMBL30256294 | 0.87 | NR1H2 (0.36) | NR1H2NR1H3DDB1CRBNGABRG2 | |
| SCHEMBL30256654 | 0.82 | NR1H2 (0.48) | NR1H2NR1H3DDB1CRBNGABRG2 | |
| SCHEMBL23392066 | 0.80 | NR1H2 (0.48) | NR1H2NR1H3GABRG2GABRB3GABRA5 | |
| SCHEMBL30754584 | 0.80 | NR1H2 (0.48) | NR1H2NR1H3GABRG2GABRB3GABRA5 | |
| SCHEMBL23391716 | 0.78 | GABRG2 (0.38) | NR1H2NR1H3GABRG2GABRB3GABRA5 | |
| SCHEMBL29773883 | 0.74 | CHRM2 (0.49) | NR1H2GABRG2GABRB3GABRA5CHRM2 | |
| SCHEMBL23391720 | 0.73 | ACHE (0.41) | GABRG2GABRB3GABRA5 | |
| SCHEMBL16597821 | 0.72 | GABRG2 (0.42) | NR1H2GABRG2GABRB3GABRA5CHRM2 | |
| SCHEMBL20581637 | 0.70 | GABRG2 (0.38) | NR1H2NR1H3GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622901-B2 | Compounds for tau protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20240091213-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4310496-A2 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3652329-B1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA FARBER CANCER INST INC (US) | 2023-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091213-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | UBQLN1, UBQLN2, CRBN | NR1H2 3083/4885NR1H3 3037/4885DDB1 449/4885 |
| US-12622901-B2 | Compounds for tau protein degradation | MAPT, UBQLN1, PSEN1 | NR1H2 3082/4885NR1H3 2966/4885DDB1 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.